Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"- Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 -- Enrollment target achieved for mavrilimumab Phase 2 trial in giant cell arteritis; top-line data expected in 2H 2020 - - Top-line data from KPL-716 Phase 2a trial in prurigo nodularis expected in 1H 2020 -- Interim data from cohorts of KPL-716 Phase 2 trial in diseases characterized by chronic pruritus expected in 1H 2020 -- Top-line data from KPL-404 first-in-human study with antigen challenge TDAR expected in 2H 2020 - \n HAMILTON, Bermuda, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced recent pipeline progress and upcoming 2020 clinical milestones. Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa will provide further detail in a corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference today, Monday, January 13, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California. “Kiniksa’s clinical-stage assets, including rilonacept, mavrilimumab, KPL-716 and KPL-404, are on track to generate clinical data this year,” said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. “Each readout has the potential to be an important value-driving event and to help inform our portfolio strategy and capital allocation decisions. We have the capital to achieve multiple clinical data readouts and project that our 2019 year-end cash reserves of approximately $233 million will fund our operating plan into the second half of 2021.” Recent Pipeline Progress and Expected 2020 Clinical Data ReadoutsRilonacept (IL-1α and IL-1β cytokine trap) Kiniksa has achieved its enrollment target for RHAPSODY, a global, randomized-withdrawal design, pivotal Phase 3 trial of rilonacept in patients with recurrent pericarditis. The company expects top-line data in the second half of 2020.Kiniksa recently announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis. Kiniksa’s Breakthrough Therapy application was ...

More updates from Kiniksa Pharmaceuticals International, Plc